升高的IsoPSA筛选出临床显著前列腺癌,但对任何特定的不良组织病理学或影像学特征无偏好
单中心回顾性研究纳入83例术前行IsoPSA检测并接受根治性前列腺切除术的患者,与44例同期未行IsoPSA检测的对照比较。IsoPSA组术前PSA显著更高(7.8 ng/mL vs 5.2 ng/mL,P<.001)。升高的IsoPSA指数(>6.0)未选择出任何特定的不良组织病理学特征,除PSA密度外也未选择出不良MRI特征。IsoPSA检测不是GG升级的预测因子(OR 0.63,P=.58)。
要点
- IsoPSA组术前PSA显著高于对照组(7.8 ng/mL vs 5.2 ng/mL,P<.001)。
- 升高的IsoPSA指数(>6.0)未选择出任何特定的不良组织病理学特征。
- IsoPSA检测不是GG升级的预测因子(OR 0.63,P=.58)。
核心结论
- 升高的IsoPSA是一种诊断工具,可在活检时检测出临床显著前列腺癌,但在此过程中并未选择出任何特定的不良前列腺MRI或病理学特征。
研究设计与样本
- 单中心回顾性研究,纳入2019-2021年在本机构接受IsoPSA检测、前列腺活检和根治性前列腺切除术的患者83例,同期未行术前IsoPSA检测而接受根治性前列腺切除术的连续队列44例作为对照。
主要发现
- IsoPSA组术前PSA显著高于对照组(IsoPSA组:7.8 ng/mL vs 对照组:5.2 ng/mL,P<.001)。
- 升高的IsoPSA指数(>6.0)在根治性前列腺切除术时未选择出任何特定的不良组织病理学特征。
- 除PSA密度外,升高的IsoPSA未选择出不良MRI特征。
- 从活检到根治性前列腺切除术,两组的GG一致性、降级和升级率无差异。
- IsoPSA检测不是GG升级的预测因子(OR 0.63,P=.58)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore if elevated IsoPSA selects for particular adverse radiographic or histopathologic features among men destined to undergo radical prostatectomy (RP) because of clinically significant prostate cancer identified at biopsy. MATERIALS AND METHODS: Single center, retrospective review of patients who had undergone IsoPSA testing, prostate biopsy and RP at our institution from 2019-2021. A consecutive cohort of patients whom had undergone RP within the same period without pre-operative IsoPSA served as controls. Pre-operative prostate Magnetic Resonance Imaging (MRI) was included in our analysis. Adverse histopathologic and MRI features were compared between both groups. Concordance, downstaging, and upstaging grade group rates (GG) was evaluated. Pearson Chi-Square test was used to compare categorical variables, Wilcoxon-Rank sum test for quantitative variables, and binary logistic regression to identify predictors of upstaging at RP. RESULTS: Eighty-three patients underwent IsoPSA and RP while 44 patients were controls. The IsoPSA group had significantly higher pre-operative PSA (IsoPSA group: 7.8 ng/mL vs Control group: 5.2 ng/mL, P<.001 ). Elevated IsoPSA index (>6.0) did not select for any specific adverse histopathologic features at RP. Excluding PSA density, elevated IsoPSA was not selective for adverse MRI features. There were no differences in concordance, downstaging, and upstaging GG rates from biopsy to RP. IsoPSA testing was not a predictor of GG upstaging (Odds Ratio: 0.63, P .58). CONCLUSION: Elevated IsoPSA is a diagnostic tool that can detect clinically significant prostate at the time of biopsy. In doing so, it does not select for any particular adverse prostate MRI or pathologic feature at RP.
引用
- Benidir T, Hofmann M, Lone Z, et al. Elevated IsoPSA Selects for Clinically Significant Prostate Cancer Without a Preference for Any Particular Adverse Histopathologic or Radiographic Feature. Urology. 2022. PMID: 35680047. doi:10.1016/j.urology.2022.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。